[Animal models for steroid-induced osteonecrosis].
We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia. Detailed clinical and laboratory evaluations of coagulation system are recommended in those patients who develop manifestations of an abnormal lipid metabolism shortly after high-dose corticosteroid therapy. Moreover, we investigated the effects of the combination treatment with an anticoagulant (warfarin) plus a lipid-lowering agent (probucol) on prevention of steroid-induced osteonecrosis (ON) in this animal model. The incidence of ON in warfarin plus probucol (5%) was significantly lower than that observed in the control group (70%) (p <0.0001). Our results experimentally showed that the combined use of an anticoagulant and a lipid-lowering agent helps prevent steroid-induced ON in rabbits.
Yamamoto
Takuaki
T
Kyushu University, Department of Orthopaedic Surgery.
Miyanishi
Keita
K
Motomura
Goro
G
Nishida
Kenjiro
K
Iwamoto
Yukihide
Y
Sueishi
Katsuo
K
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy; D008775:Methylprednisolone / Q000009:adverse effects*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D011341:Probucol / Q000627:therapeutic use; D011817:Rabbits; D013921:Thrombocytopenia / Q000139:chemically induced; D014859:Warfarin / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D005938:Glucocorticoids; D014859:Warfarin; D011341:Probucol; D008775:Methylprednisolone